Xiao Ping Ye
Chairman presso HANGZHOU TIGERMED CONSULTING CO., LTD
Patrimonio netto: 1 303 M $ in data 31/03/2024
Profilo
Attualmente, Xiao Ping Ye è presidente e direttore generale di Hangzhou Tigermed Consulting Co. Il Dr. Ye è anche nel consiglio di amministrazione di Dian Diagnostics Group Co. Ltd., Coland Holdings Ltd., Shanghai Guochuang Pharmaceutical Co., Ltd. e HBM Holdings Ltd. Il Dr. Ye è stato in precedenza Chief Medical Officer di Roche (China) Co. Ltd. Ha ricevuto un dottorato dall'Università di Oxford.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
30/06/2023 | 132 929 656 ( 74.09% ) | 978 M $ | 31/03/2024 | |
01/02/2024 | 44 309 885 ( 7.78% ) | 326 M $ | 31/03/2024 |
Posizioni attive di Xiao Ping Ye
Società | Posizione | Inizio |
---|---|---|
COLAND HOLDINGS LIMITED | Director/Board Member | 05/12/2010 |
HANGZHOU TIGERMED CONSULTING CO., LTD | Chairman | - |
HBM HOLDINGS LIMITED | Director/Board Member | 01/12/2020 |
Precedenti posizioni note di Xiao Ping Ye
Società | Posizione | Fine |
---|---|---|
DIAN DIAGNOSTICS GROUP CO.,LTD. | Director/Board Member | 01/12/2022 |
Shanghai Guo Chuang Pharmaceutical Co., Ltd.
Shanghai Guo Chuang Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Guo Chuang Pharmaceutical Co., Ltd. principally engages in the research, development, production, and sale of pharmaceutical products. Its products include pharmaceuticals against nervous system diseases, digestive system diseases, cardiovascular diseases, mental diseases, and immune system diseases. The company was founded on March 20, 2003 and is headquartered in Shanghai, China. | Director/Board Member | 01/10/2021 |
Shanghai LIDE Biotech Co. Ltd.
Shanghai LIDE Biotech Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai LIDE Biotech Co. Ltd. is a translational medicine service provider that specializes in oncology translational research and immuno oncology. The private company is based in Shanghai, China. The Chinese company has a growing bank of over 50 cell line-derived xenograft (cdx) mouse models that are used for preclinical drug efficacy testing. The benefits of cdx models are their cost effectiveness, fast turnaround time, and high efficiency of xenotransplantation. LIDE's FGI (Functional Genomic Imaging) platform leverages its K-cell technology and bioinformatics team to deliver next-generation transcription analysis. The primary benefit of CR (Conditionally Reprogrammed) cells is their intratumor and intertumor heterogeneity, even after amplification. | Director/Board Member | - |
Hangzhou Tigermed Consulting Co., Ltd
Hangzhou Tigermed Consulting Co., Ltd Medical/Nursing ServicesHealth Services Tigermed Consulting Co., Ltd. is a Contract Research Organization (CRO) in China that provides regulatory service, Phase I-IV clinical trials, data management & biostatistics, medical translations and GCP training services for healthcare products. The company was founded in 2002 and is headquartered in Shanghai, CN. | Director/Board Member | - |
Roche (China) Co. Ltd. | Chief Tech/Sci/R&D Officer | - |
Formazione di Xiao Ping Ye
University of Oxford | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
DIAN DIAGNOSTICS GROUP CO.,LTD. | Health Services |
HANGZHOU TIGERMED CONSULTING CO., LTD | Commercial Services |
HBM HOLDINGS LIMITED | Health Technology |
Aziende private | 5 |
---|---|
Hangzhou Tigermed Consulting Co., Ltd
Hangzhou Tigermed Consulting Co., Ltd Medical/Nursing ServicesHealth Services Tigermed Consulting Co., Ltd. is a Contract Research Organization (CRO) in China that provides regulatory service, Phase I-IV clinical trials, data management & biostatistics, medical translations and GCP training services for healthcare products. The company was founded in 2002 and is headquartered in Shanghai, CN. | Health Services |
Roche (China) Co. Ltd. | |
Coland Holdings Ltd.
Coland Holdings Ltd. Pharmaceuticals: MajorHealth Technology Coland Holdings Ltd. engages in the research, development, and sale of generic and traditional Chinese medicine, biochemical drugs, and medical equipment. It focuses on the treatment of hepatobiliary, respiratory system, tumor, and cardiovascular problems. The company was founded on March 23, 2010 and is headquartered in Shanghai, China. | Health Technology |
Shanghai Guo Chuang Pharmaceutical Co., Ltd.
Shanghai Guo Chuang Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Guo Chuang Pharmaceutical Co., Ltd. principally engages in the research, development, production, and sale of pharmaceutical products. Its products include pharmaceuticals against nervous system diseases, digestive system diseases, cardiovascular diseases, mental diseases, and immune system diseases. The company was founded on March 20, 2003 and is headquartered in Shanghai, China. | Health Technology |
Shanghai LIDE Biotech Co. Ltd.
Shanghai LIDE Biotech Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai LIDE Biotech Co. Ltd. is a translational medicine service provider that specializes in oncology translational research and immuno oncology. The private company is based in Shanghai, China. The Chinese company has a growing bank of over 50 cell line-derived xenograft (cdx) mouse models that are used for preclinical drug efficacy testing. The benefits of cdx models are their cost effectiveness, fast turnaround time, and high efficiency of xenotransplantation. LIDE's FGI (Functional Genomic Imaging) platform leverages its K-cell technology and bioinformatics team to deliver next-generation transcription analysis. The primary benefit of CR (Conditionally Reprogrammed) cells is their intratumor and intertumor heterogeneity, even after amplification. | Commercial Services |
- Borsa valori
- Insiders
- Xiao Ping Ye